IL37 and psoriasis: A total of 122 adults with moderate-to-severe psoriasis receiving interleukin-17 or interleukin-23 inhibitors completed validated Croatian versions of the Beliefs about Medicines Questionnaire–General (BMQ-G), Beliefs about Medicines Questionnaire–Specific (BMQ-S), and the Medication Adherence Report Scale (MARS-5).